Search

272 Result(s)
Sort by

SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Immuno-Oncology

Immuno-Oncology

We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Experiences of living with cancer

Experiences of living with cancer

We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
The power of patient advocacy in cancer care

The power of patient advocacy in cancer care

Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Small Cell Lung Cancer

Small Cell Lung Cancer

Discover more about small cell lung cancer, including its symptoms and treatment options.
Non-small cell lung cancer

Non-small cell lung cancer

Discover more about non-small cell lung cancer, including its symptoms and treatment options.
Living With Cancer

Living With Cancer

Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Boehringer Ingelheim acquires Nerio Therapeutics

Boehringer Ingelheim acquires Nerio Therapeutics

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Protein Degraders in Cancer

Protein Degraders in Cancer

Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Veganism

Veganism

Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Four Pillars Cancer Immunology

Four Pillars Cancer Immunology

Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation